nodes	percent_of_prediction	percent_of_DWPC	metapath
Esomeprazole—CYP3A4—Everolimus—kidney cancer	0.116	0.26	CbGbCtD
Esomeprazole—CYP3A4—Temsirolimus—kidney cancer	0.0784	0.176	CbGbCtD
Esomeprazole—CYP2C19—Sorafenib—kidney cancer	0.0494	0.111	CbGbCtD
Esomeprazole—CYP3A4—Pazopanib—kidney cancer	0.0412	0.0924	CbGbCtD
Esomeprazole—CYP3A4—Erlotinib—kidney cancer	0.0294	0.0659	CbGbCtD
Esomeprazole—CYP3A4—Paclitaxel—kidney cancer	0.0269	0.0603	CbGbCtD
Esomeprazole—CYP3A4—Sorafenib—kidney cancer	0.0239	0.0536	CbGbCtD
Esomeprazole—CYP3A4—Vinblastine—kidney cancer	0.0236	0.0529	CbGbCtD
Esomeprazole—CYP3A4—Vincristine—kidney cancer	0.0232	0.052	CbGbCtD
Esomeprazole—CYP3A4—Sunitinib—kidney cancer	0.0194	0.0434	CbGbCtD
Esomeprazole—CYP3A4—Doxorubicin—kidney cancer	0.0145	0.0325	CbGbCtD
Esomeprazole—ATP4B—Ion transport by P-type ATPases—ATP7B—kidney cancer	0.00314	0.116	CbGpPWpGaD
Esomeprazole—ATP4A—Ion transport by P-type ATPases—ATP7B—kidney cancer	0.0028	0.103	CbGpPWpGaD
Esomeprazole—ATP4B—Ion channel transport—RYR1—kidney cancer	0.00189	0.0699	CbGpPWpGaD
Esomeprazole—Rabeprazole—CYP1A1—kidney cancer	0.00182	0.255	CrCbGaD
Esomeprazole—ATP4A—Ion channel transport—RYR1—kidney cancer	0.00169	0.0623	CbGpPWpGaD
Esomeprazole—Omeprazole—CYP1A1—kidney cancer	0.00149	0.208	CrCbGaD
Esomeprazole—Lansoprazole—CYP1A1—kidney cancer	0.00136	0.19	CrCbGaD
Esomeprazole—ATP4B—Ion channel transport—ATP7B—kidney cancer	0.00109	0.0401	CbGpPWpGaD
Esomeprazole—ATP4A—Ion channel transport—ATP7B—kidney cancer	0.00097	0.0358	CbGpPWpGaD
Esomeprazole—Pantoprazole—ABCB1—kidney cancer	0.000969	0.135	CrCbGaD
Esomeprazole—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000797	0.0294	CbGpPWpGaD
Esomeprazole—Omeprazole—ABCB1—kidney cancer	0.00079	0.11	CrCbGaD
Esomeprazole—Lansoprazole—ABCB1—kidney cancer	0.000722	0.101	CrCbGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000659	0.0243	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000587	0.0217	CbGpPWpGaD
Esomeprazole—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.000515	0.019	CbGpPWpGaD
Esomeprazole—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000501	0.0185	CbGpPWpGaD
Esomeprazole—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	0.000468	0.0173	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000379	0.014	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000379	0.014	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000379	0.014	CbGpPWpGaD
Esomeprazole—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000363	0.0134	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000337	0.0125	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000337	0.0125	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000337	0.0125	CbGpPWpGaD
Esomeprazole—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000336	0.0124	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—ACHE—kidney cancer	0.000304	0.0112	CbGpPWpGaD
Esomeprazole—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000285	0.0105	CbGpPWpGaD
Esomeprazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.000282	0.0104	CbGpPWpGaD
Esomeprazole—ATP4B—Ion channel transport—RAF1—kidney cancer	0.000247	0.00913	CbGpPWpGaD
Esomeprazole—CYP2C19—Xenobiotics—CYP1A1—kidney cancer	0.000247	0.00913	CbGpPWpGaD
Esomeprazole—CYP2C19—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000238	0.00878	CbGpPWpGaD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000235	0.00866	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—ACY1—kidney cancer	0.000227	0.0084	CbGpPWpGaD
Esomeprazole—ATP4A—Ion channel transport—RAF1—kidney cancer	0.000221	0.00814	CbGpPWpGaD
Esomeprazole—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000215	0.00794	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.0002	0.00737	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000193	0.00712	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000184	0.00681	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—PTGS1—kidney cancer	0.000184	0.00681	CbGpPWpGaD
Esomeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000184	0.00679	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.000184	0.00678	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000178	0.00657	CbGpPWpGaD
Esomeprazole—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000178	0.00656	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000172	0.00634	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000171	0.0063	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000162	0.00597	CbGpPWpGaD
Esomeprazole—Nausea—Erlotinib—kidney cancer	0.00016	0.000308	CcSEcCtD
Esomeprazole—Alopecia—Capecitabine—kidney cancer	0.00016	0.000308	CcSEcCtD
Esomeprazole—Dry mouth—Paclitaxel—kidney cancer	0.00016	0.000308	CcSEcCtD
Esomeprazole—Diarrhoea—Sunitinib—kidney cancer	0.00016	0.000307	CcSEcCtD
Esomeprazole—Mental disorder—Capecitabine—kidney cancer	0.000159	0.000305	CcSEcCtD
Esomeprazole—Asthenia—Dactinomycin—kidney cancer	0.000159	0.000305	CcSEcCtD
Esomeprazole—Confusional state—Paclitaxel—kidney cancer	0.000158	0.000304	CcSEcCtD
Esomeprazole—Blood creatinine increased—Doxorubicin—kidney cancer	0.000158	0.000304	CcSEcCtD
Esomeprazole—Malnutrition—Capecitabine—kidney cancer	0.000158	0.000303	CcSEcCtD
Esomeprazole—Anaphylactic shock—Paclitaxel—kidney cancer	0.000157	0.000302	CcSEcCtD
Esomeprazole—Body temperature increased—Vincristine—kidney cancer	0.000156	0.0003	CcSEcCtD
Esomeprazole—Abdominal pain—Vincristine—kidney cancer	0.000156	0.0003	CcSEcCtD
Esomeprazole—Infection—Paclitaxel—kidney cancer	0.000156	0.0003	CcSEcCtD
Esomeprazole—Flatulence—Capecitabine—kidney cancer	0.000155	0.000299	CcSEcCtD
Esomeprazole—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000155	0.00572	CbGpPWpGaD
Esomeprazole—Dry skin—Doxorubicin—kidney cancer	0.000155	0.000298	CcSEcCtD
Esomeprazole—Dysgeusia—Capecitabine—kidney cancer	0.000154	0.000297	CcSEcCtD
Esomeprazole—Dizziness—Sunitinib—kidney cancer	0.000154	0.000297	CcSEcCtD
Esomeprazole—Feeling abnormal—Gemcitabine—kidney cancer	0.000154	0.000297	CcSEcCtD
Esomeprazole—Shock—Paclitaxel—kidney cancer	0.000154	0.000297	CcSEcCtD
Esomeprazole—Vomiting—Sorafenib—kidney cancer	0.000154	0.000297	CcSEcCtD
Esomeprazole—Abdominal pain upper—Doxorubicin—kidney cancer	0.000154	0.000297	CcSEcCtD
Esomeprazole—Nervous system disorder—Paclitaxel—kidney cancer	0.000154	0.000296	CcSEcCtD
Esomeprazole—Hypokalaemia—Doxorubicin—kidney cancer	0.000154	0.000296	CcSEcCtD
Esomeprazole—Thrombocytopenia—Paclitaxel—kidney cancer	0.000154	0.000296	CcSEcCtD
Esomeprazole—Tachycardia—Paclitaxel—kidney cancer	0.000153	0.000295	CcSEcCtD
Esomeprazole—Rash—Sorafenib—kidney cancer	0.000153	0.000294	CcSEcCtD
Esomeprazole—Dermatitis—Sorafenib—kidney cancer	0.000153	0.000294	CcSEcCtD
Esomeprazole—Back pain—Capecitabine—kidney cancer	0.000153	0.000294	CcSEcCtD
Esomeprazole—Breast disorder—Doxorubicin—kidney cancer	0.000153	0.000294	CcSEcCtD
Esomeprazole—Skin disorder—Paclitaxel—kidney cancer	0.000152	0.000293	CcSEcCtD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000152	0.00562	CbGpPWpGaD
Esomeprazole—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000152	0.000293	CcSEcCtD
Esomeprazole—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000152	0.000293	CcSEcCtD
Esomeprazole—Headache—Sorafenib—kidney cancer	0.000152	0.000292	CcSEcCtD
Esomeprazole—Muscle spasms—Capecitabine—kidney cancer	0.000152	0.000292	CcSEcCtD
Esomeprazole—Hyperhidrosis—Paclitaxel—kidney cancer	0.000152	0.000292	CcSEcCtD
Esomeprazole—Diarrhoea—Dactinomycin—kidney cancer	0.000151	0.000291	CcSEcCtD
Esomeprazole—Anorexia—Paclitaxel—kidney cancer	0.00015	0.000288	CcSEcCtD
Esomeprazole—Gastritis—Doxorubicin—kidney cancer	0.000149	0.000287	CcSEcCtD
Esomeprazole—Muscular weakness—Doxorubicin—kidney cancer	0.000149	0.000286	CcSEcCtD
Esomeprazole—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000149	0.000286	CcSEcCtD
Esomeprazole—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000149	0.00549	CbGpPWpGaD
Esomeprazole—Vision blurred—Capecitabine—kidney cancer	0.000149	0.000286	CcSEcCtD
Esomeprazole—Vomiting—Sunitinib—kidney cancer	0.000148	0.000286	CcSEcCtD
Esomeprazole—Body temperature increased—Gemcitabine—kidney cancer	0.000148	0.000285	CcSEcCtD
Esomeprazole—Tremor—Capecitabine—kidney cancer	0.000148	0.000284	CcSEcCtD
Esomeprazole—Rash—Sunitinib—kidney cancer	0.000147	0.000283	CcSEcCtD
Esomeprazole—Dermatitis—Sunitinib—kidney cancer	0.000147	0.000283	CcSEcCtD
Esomeprazole—Abdominal distension—Doxorubicin—kidney cancer	0.000147	0.000283	CcSEcCtD
Esomeprazole—Ill-defined disorder—Capecitabine—kidney cancer	0.000146	0.000282	CcSEcCtD
Esomeprazole—Headache—Sunitinib—kidney cancer	0.000146	0.000281	CcSEcCtD
Esomeprazole—Asthma—Doxorubicin—kidney cancer	0.000146	0.000281	CcSEcCtD
Esomeprazole—Influenza—Doxorubicin—kidney cancer	0.000146	0.000281	CcSEcCtD
Esomeprazole—Dysphagia—Doxorubicin—kidney cancer	0.000146	0.000281	CcSEcCtD
Esomeprazole—Anaemia—Capecitabine—kidney cancer	0.000146	0.00028	CcSEcCtD
Esomeprazole—Hypersensitivity—Vincristine—kidney cancer	0.000146	0.00028	CcSEcCtD
Esomeprazole—Nausea—Sorafenib—kidney cancer	0.000144	0.000277	CcSEcCtD
Esomeprazole—Pancreatitis—Doxorubicin—kidney cancer	0.000143	0.000275	CcSEcCtD
Esomeprazole—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000143	0.00528	CbGpPWpGaD
Esomeprazole—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000143	0.000275	CcSEcCtD
Esomeprazole—Malaise—Capecitabine—kidney cancer	0.000142	0.000274	CcSEcCtD
Esomeprazole—Angina pectoris—Doxorubicin—kidney cancer	0.000142	0.000273	CcSEcCtD
Esomeprazole—Insomnia—Paclitaxel—kidney cancer	0.000142	0.000273	CcSEcCtD
Esomeprazole—Vertigo—Capecitabine—kidney cancer	0.000142	0.000273	CcSEcCtD
Esomeprazole—Asthenia—Vincristine—kidney cancer	0.000142	0.000273	CcSEcCtD
Esomeprazole—Leukopenia—Capecitabine—kidney cancer	0.000141	0.000272	CcSEcCtD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000141	0.00521	CbGpPWpGaD
Esomeprazole—Paraesthesia—Paclitaxel—kidney cancer	0.000141	0.000271	CcSEcCtD
Esomeprazole—Vomiting—Dactinomycin—kidney cancer	0.000141	0.00027	CcSEcCtD
Esomeprazole—Dyspnoea—Paclitaxel—kidney cancer	0.00014	0.000269	CcSEcCtD
Esomeprazole—Somnolence—Paclitaxel—kidney cancer	0.000139	0.000268	CcSEcCtD
Esomeprazole—Palpitations—Capecitabine—kidney cancer	0.000139	0.000268	CcSEcCtD
Esomeprazole—Rash—Dactinomycin—kidney cancer	0.000139	0.000268	CcSEcCtD
Esomeprazole—Nausea—Sunitinib—kidney cancer	0.000139	0.000267	CcSEcCtD
Esomeprazole—Pancytopenia—Doxorubicin—kidney cancer	0.000139	0.000267	CcSEcCtD
Esomeprazole—Dyspepsia—Paclitaxel—kidney cancer	0.000138	0.000266	CcSEcCtD
Esomeprazole—Cough—Capecitabine—kidney cancer	0.000138	0.000265	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000137	0.00505	CbGpPWpGaD
Esomeprazole—Neutropenia—Doxorubicin—kidney cancer	0.000136	0.000263	CcSEcCtD
Esomeprazole—Dysuria—Doxorubicin—kidney cancer	0.000136	0.000263	CcSEcCtD
Esomeprazole—Decreased appetite—Paclitaxel—kidney cancer	0.000136	0.000262	CcSEcCtD
Esomeprazole—Hypertension—Capecitabine—kidney cancer	0.000136	0.000262	CcSEcCtD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000136	0.00501	CbGpPWpGaD
Esomeprazole—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000136	0.000261	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000135	0.000261	CcSEcCtD
Esomeprazole—Fatigue—Paclitaxel—kidney cancer	0.000135	0.00026	CcSEcCtD
Esomeprazole—Diarrhoea—Vincristine—kidney cancer	0.000135	0.00026	CcSEcCtD
Esomeprazole—Pollakiuria—Doxorubicin—kidney cancer	0.000135	0.000259	CcSEcCtD
Esomeprazole—Asthenia—Gemcitabine—kidney cancer	0.000134	0.000259	CcSEcCtD
Esomeprazole—Myalgia—Capecitabine—kidney cancer	0.000134	0.000258	CcSEcCtD
Esomeprazole—Chest pain—Capecitabine—kidney cancer	0.000134	0.000258	CcSEcCtD
Esomeprazole—Arthralgia—Capecitabine—kidney cancer	0.000134	0.000258	CcSEcCtD
Esomeprazole—Pain—Paclitaxel—kidney cancer	0.000134	0.000258	CcSEcCtD
Esomeprazole—Constipation—Paclitaxel—kidney cancer	0.000134	0.000258	CcSEcCtD
Esomeprazole—Anxiety—Capecitabine—kidney cancer	0.000134	0.000257	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000133	0.000257	CcSEcCtD
Esomeprazole—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000133	0.000256	CcSEcCtD
Esomeprazole—Weight increased—Doxorubicin—kidney cancer	0.000133	0.000256	CcSEcCtD
Esomeprazole—Discomfort—Capecitabine—kidney cancer	0.000133	0.000255	CcSEcCtD
Esomeprazole—Pruritus—Gemcitabine—kidney cancer	0.000133	0.000255	CcSEcCtD
Esomeprazole—Weight decreased—Doxorubicin—kidney cancer	0.000132	0.000254	CcSEcCtD
Esomeprazole—Dry mouth—Capecitabine—kidney cancer	0.000131	0.000253	CcSEcCtD
Esomeprazole—Nausea—Dactinomycin—kidney cancer	0.000131	0.000253	CcSEcCtD
Esomeprazole—Dizziness—Vincristine—kidney cancer	0.000131	0.000251	CcSEcCtD
Esomeprazole—Infestation—Doxorubicin—kidney cancer	0.00013	0.00025	CcSEcCtD
Esomeprazole—Infestation NOS—Doxorubicin—kidney cancer	0.00013	0.00025	CcSEcCtD
Esomeprazole—Confusional state—Capecitabine—kidney cancer	0.00013	0.00025	CcSEcCtD
Esomeprazole—Feeling abnormal—Paclitaxel—kidney cancer	0.000129	0.000249	CcSEcCtD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000129	0.00477	CbGpPWpGaD
Esomeprazole—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000129	0.000248	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000128	0.000247	CcSEcCtD
Esomeprazole—Diarrhoea—Gemcitabine—kidney cancer	0.000128	0.000247	CcSEcCtD
Esomeprazole—Renal failure—Doxorubicin—kidney cancer	0.000128	0.000246	CcSEcCtD
Esomeprazole—Infection—Capecitabine—kidney cancer	0.000128	0.000246	CcSEcCtD
Esomeprazole—Jaundice—Doxorubicin—kidney cancer	0.000127	0.000244	CcSEcCtD
Esomeprazole—Stomatitis—Doxorubicin—kidney cancer	0.000127	0.000244	CcSEcCtD
Esomeprazole—Shock—Capecitabine—kidney cancer	0.000127	0.000244	CcSEcCtD
Esomeprazole—Conjunctivitis—Doxorubicin—kidney cancer	0.000126	0.000243	CcSEcCtD
Esomeprazole—Urinary tract infection—Doxorubicin—kidney cancer	0.000126	0.000243	CcSEcCtD
Esomeprazole—Nervous system disorder—Capecitabine—kidney cancer	0.000126	0.000243	CcSEcCtD
Esomeprazole—Thrombocytopenia—Capecitabine—kidney cancer	0.000126	0.000243	CcSEcCtD
Esomeprazole—Tachycardia—Capecitabine—kidney cancer	0.000126	0.000242	CcSEcCtD
Esomeprazole—Vomiting—Vincristine—kidney cancer	0.000126	0.000242	CcSEcCtD
Esomeprazole—Skin disorder—Capecitabine—kidney cancer	0.000125	0.000241	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—ALDH1A1—kidney cancer	0.000125	0.0046	CbGpPWpGaD
Esomeprazole—Urticaria—Paclitaxel—kidney cancer	0.000125	0.00024	CcSEcCtD
Esomeprazole—Rash—Vincristine—kidney cancer	0.000125	0.00024	CcSEcCtD
Esomeprazole—Hyperhidrosis—Capecitabine—kidney cancer	0.000124	0.000239	CcSEcCtD
Esomeprazole—Dermatitis—Vincristine—kidney cancer	0.000124	0.000239	CcSEcCtD
Esomeprazole—Haematuria—Doxorubicin—kidney cancer	0.000124	0.000239	CcSEcCtD
Esomeprazole—Abdominal pain—Paclitaxel—kidney cancer	0.000124	0.000239	CcSEcCtD
Esomeprazole—Body temperature increased—Paclitaxel—kidney cancer	0.000124	0.000239	CcSEcCtD
Esomeprazole—Headache—Vincristine—kidney cancer	0.000124	0.000238	CcSEcCtD
Esomeprazole—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000123	0.000237	CcSEcCtD
Esomeprazole—Epistaxis—Doxorubicin—kidney cancer	0.000123	0.000236	CcSEcCtD
Esomeprazole—Anorexia—Capecitabine—kidney cancer	0.000123	0.000236	CcSEcCtD
Esomeprazole—Sinusitis—Doxorubicin—kidney cancer	0.000122	0.000235	CcSEcCtD
Esomeprazole—Agranulocytosis—Doxorubicin—kidney cancer	0.000121	0.000234	CcSEcCtD
Esomeprazole—Vomiting—Gemcitabine—kidney cancer	0.000119	0.000229	CcSEcCtD
Esomeprazole—Bradycardia—Doxorubicin—kidney cancer	0.000119	0.000229	CcSEcCtD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000119	0.00439	CbGpPWpGaD
Esomeprazole—Rash—Gemcitabine—kidney cancer	0.000118	0.000227	CcSEcCtD
Esomeprazole—Dermatitis—Gemcitabine—kidney cancer	0.000118	0.000227	CcSEcCtD
Esomeprazole—Headache—Gemcitabine—kidney cancer	0.000117	0.000226	CcSEcCtD
Esomeprazole—Nausea—Vincristine—kidney cancer	0.000117	0.000226	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000117	0.000226	CcSEcCtD
Esomeprazole—Rhinitis—Doxorubicin—kidney cancer	0.000117	0.000225	CcSEcCtD
Esomeprazole—Hepatitis—Doxorubicin—kidney cancer	0.000117	0.000225	CcSEcCtD
Esomeprazole—Insomnia—Capecitabine—kidney cancer	0.000116	0.000224	CcSEcCtD
Esomeprazole—Hypoaesthesia—Doxorubicin—kidney cancer	0.000116	0.000224	CcSEcCtD
Esomeprazole—Pharyngitis—Doxorubicin—kidney cancer	0.000116	0.000223	CcSEcCtD
Esomeprazole—Paraesthesia—Capecitabine—kidney cancer	0.000116	0.000222	CcSEcCtD
Esomeprazole—Hypersensitivity—Paclitaxel—kidney cancer	0.000116	0.000222	CcSEcCtD
Esomeprazole—Urinary tract disorder—Doxorubicin—kidney cancer	0.000115	0.000222	CcSEcCtD
Esomeprazole—Oedema peripheral—Doxorubicin—kidney cancer	0.000115	0.000221	CcSEcCtD
Esomeprazole—Connective tissue disorder—Doxorubicin—kidney cancer	0.000115	0.000221	CcSEcCtD
Esomeprazole—Dyspnoea—Capecitabine—kidney cancer	0.000115	0.000221	CcSEcCtD
Esomeprazole—Urethral disorder—Doxorubicin—kidney cancer	0.000114	0.00022	CcSEcCtD
Esomeprazole—Dyspepsia—Capecitabine—kidney cancer	0.000113	0.000218	CcSEcCtD
Esomeprazole—Visual impairment—Doxorubicin—kidney cancer	0.000113	0.000217	CcSEcCtD
Esomeprazole—Asthenia—Paclitaxel—kidney cancer	0.000113	0.000217	CcSEcCtD
Esomeprazole—Decreased appetite—Capecitabine—kidney cancer	0.000112	0.000215	CcSEcCtD
Esomeprazole—Nausea—Gemcitabine—kidney cancer	0.000111	0.000214	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000111	0.000214	CcSEcCtD
Esomeprazole—Fatigue—Capecitabine—kidney cancer	0.000111	0.000214	CcSEcCtD
Esomeprazole—Pruritus—Paclitaxel—kidney cancer	0.000111	0.000214	CcSEcCtD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000111	0.0041	CbGpPWpGaD
Esomeprazole—Erythema multiforme—Doxorubicin—kidney cancer	0.00011	0.000212	CcSEcCtD
Esomeprazole—Pain—Capecitabine—kidney cancer	0.00011	0.000212	CcSEcCtD
Esomeprazole—Constipation—Capecitabine—kidney cancer	0.00011	0.000212	CcSEcCtD
Esomeprazole—Eye disorder—Doxorubicin—kidney cancer	0.000109	0.00021	CcSEcCtD
Esomeprazole—Tinnitus—Doxorubicin—kidney cancer	0.000109	0.00021	CcSEcCtD
Esomeprazole—Flushing—Doxorubicin—kidney cancer	0.000108	0.000209	CcSEcCtD
Esomeprazole—Diarrhoea—Paclitaxel—kidney cancer	0.000107	0.000207	CcSEcCtD
Esomeprazole—Feeling abnormal—Capecitabine—kidney cancer	0.000106	0.000204	CcSEcCtD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000106	0.0039	CbGpPWpGaD
Esomeprazole—Immune system disorder—Doxorubicin—kidney cancer	0.000105	0.000203	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Capecitabine—kidney cancer	0.000105	0.000203	CcSEcCtD
Esomeprazole—Mediastinal disorder—Doxorubicin—kidney cancer	0.000105	0.000203	CcSEcCtD
Esomeprazole—Chills—Doxorubicin—kidney cancer	0.000105	0.000202	CcSEcCtD
Esomeprazole—Dizziness—Paclitaxel—kidney cancer	0.000104	0.0002	CcSEcCtD
Esomeprazole—Alopecia—Doxorubicin—kidney cancer	0.000103	0.000199	CcSEcCtD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000103	0.00379	CbGpPWpGaD
Esomeprazole—Mental disorder—Doxorubicin—kidney cancer	0.000102	0.000197	CcSEcCtD
Esomeprazole—Urticaria—Capecitabine—kidney cancer	0.000102	0.000197	CcSEcCtD
Esomeprazole—Body temperature increased—Capecitabine—kidney cancer	0.000102	0.000196	CcSEcCtD
Esomeprazole—Abdominal pain—Capecitabine—kidney cancer	0.000102	0.000196	CcSEcCtD
Esomeprazole—Malnutrition—Doxorubicin—kidney cancer	0.000102	0.000196	CcSEcCtD
Esomeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000101	0.00374	CbGpPWpGaD
Esomeprazole—Flatulence—Doxorubicin—kidney cancer	0.0001	0.000193	CcSEcCtD
Esomeprazole—Tension—Doxorubicin—kidney cancer	9.98e-05	0.000192	CcSEcCtD
Esomeprazole—Vomiting—Paclitaxel—kidney cancer	9.97e-05	0.000192	CcSEcCtD
Esomeprazole—Dysgeusia—Doxorubicin—kidney cancer	9.96e-05	0.000192	CcSEcCtD
Esomeprazole—Rash—Paclitaxel—kidney cancer	9.89e-05	0.00019	CcSEcCtD
Esomeprazole—Dermatitis—Paclitaxel—kidney cancer	9.88e-05	0.00019	CcSEcCtD
Esomeprazole—Nervousness—Doxorubicin—kidney cancer	9.87e-05	0.00019	CcSEcCtD
Esomeprazole—Back pain—Doxorubicin—kidney cancer	9.83e-05	0.000189	CcSEcCtD
Esomeprazole—Headache—Paclitaxel—kidney cancer	9.83e-05	0.000189	CcSEcCtD
Esomeprazole—Muscle spasms—Doxorubicin—kidney cancer	9.77e-05	0.000188	CcSEcCtD
Esomeprazole—Vision blurred—Doxorubicin—kidney cancer	9.58e-05	0.000184	CcSEcCtD
Esomeprazole—Hypersensitivity—Capecitabine—kidney cancer	9.48e-05	0.000182	CcSEcCtD
Esomeprazole—Ill-defined disorder—Doxorubicin—kidney cancer	9.43e-05	0.000182	CcSEcCtD
Esomeprazole—Anaemia—Doxorubicin—kidney cancer	9.4e-05	0.000181	CcSEcCtD
Esomeprazole—Agitation—Doxorubicin—kidney cancer	9.34e-05	0.00018	CcSEcCtD
Esomeprazole—Nausea—Paclitaxel—kidney cancer	9.32e-05	0.000179	CcSEcCtD
Esomeprazole—Asthenia—Capecitabine—kidney cancer	9.24e-05	0.000178	CcSEcCtD
Esomeprazole—Malaise—Doxorubicin—kidney cancer	9.17e-05	0.000176	CcSEcCtD
Esomeprazole—Vertigo—Doxorubicin—kidney cancer	9.13e-05	0.000176	CcSEcCtD
Esomeprazole—Pruritus—Capecitabine—kidney cancer	9.11e-05	0.000175	CcSEcCtD
Esomeprazole—Leukopenia—Doxorubicin—kidney cancer	9.1e-05	0.000175	CcSEcCtD
Esomeprazole—Palpitations—Doxorubicin—kidney cancer	8.98e-05	0.000173	CcSEcCtD
Esomeprazole—Cough—Doxorubicin—kidney cancer	8.87e-05	0.000171	CcSEcCtD
Esomeprazole—Diarrhoea—Capecitabine—kidney cancer	8.81e-05	0.000169	CcSEcCtD
Esomeprazole—Hypertension—Doxorubicin—kidney cancer	8.78e-05	0.000169	CcSEcCtD
Esomeprazole—Arthralgia—Doxorubicin—kidney cancer	8.66e-05	0.000167	CcSEcCtD
Esomeprazole—Chest pain—Doxorubicin—kidney cancer	8.66e-05	0.000167	CcSEcCtD
Esomeprazole—Myalgia—Doxorubicin—kidney cancer	8.66e-05	0.000167	CcSEcCtD
Esomeprazole—Anxiety—Doxorubicin—kidney cancer	8.63e-05	0.000166	CcSEcCtD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—RAF1—kidney cancer	8.61e-05	0.00318	CbGpPWpGaD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	8.6e-05	0.000165	CcSEcCtD
Esomeprazole—Discomfort—Doxorubicin—kidney cancer	8.55e-05	0.000165	CcSEcCtD
Esomeprazole—Dizziness—Capecitabine—kidney cancer	8.51e-05	0.000164	CcSEcCtD
Esomeprazole—Dry mouth—Doxorubicin—kidney cancer	8.47e-05	0.000163	CcSEcCtD
Esomeprazole—Confusional state—Doxorubicin—kidney cancer	8.37e-05	0.000161	CcSEcCtD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	8.32e-05	0.00307	CbGpPWpGaD
Esomeprazole—Anaphylactic shock—Doxorubicin—kidney cancer	8.3e-05	0.00016	CcSEcCtD
Esomeprazole—Infection—Doxorubicin—kidney cancer	8.24e-05	0.000159	CcSEcCtD
Esomeprazole—Vomiting—Capecitabine—kidney cancer	8.18e-05	0.000157	CcSEcCtD
Esomeprazole—Shock—Doxorubicin—kidney cancer	8.16e-05	0.000157	CcSEcCtD
Esomeprazole—Nervous system disorder—Doxorubicin—kidney cancer	8.14e-05	0.000157	CcSEcCtD
Esomeprazole—Thrombocytopenia—Doxorubicin—kidney cancer	8.12e-05	0.000156	CcSEcCtD
Esomeprazole—Rash—Capecitabine—kidney cancer	8.12e-05	0.000156	CcSEcCtD
Esomeprazole—Dermatitis—Capecitabine—kidney cancer	8.11e-05	0.000156	CcSEcCtD
Esomeprazole—Tachycardia—Doxorubicin—kidney cancer	8.1e-05	0.000156	CcSEcCtD
Esomeprazole—Headache—Capecitabine—kidney cancer	8.06e-05	0.000155	CcSEcCtD
Esomeprazole—Skin disorder—Doxorubicin—kidney cancer	8.06e-05	0.000155	CcSEcCtD
Esomeprazole—Hyperhidrosis—Doxorubicin—kidney cancer	8.02e-05	0.000154	CcSEcCtD
Esomeprazole—Anorexia—Doxorubicin—kidney cancer	7.91e-05	0.000152	CcSEcCtD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	7.77e-05	0.00287	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—RAF1—kidney cancer	7.68e-05	0.00283	CbGpPWpGaD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.66e-05	0.00283	CbGpPWpGaD
Esomeprazole—Nausea—Capecitabine—kidney cancer	7.65e-05	0.000147	CcSEcCtD
Esomeprazole—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	7.64e-05	0.00282	CbGpPWpGaD
Esomeprazole—Musculoskeletal discomfort—Doxorubicin—kidney cancer	7.56e-05	0.000145	CcSEcCtD
Esomeprazole—Insomnia—Doxorubicin—kidney cancer	7.5e-05	0.000144	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	7.49e-05	0.00277	CbGpPWpGaD
Esomeprazole—Paraesthesia—Doxorubicin—kidney cancer	7.45e-05	0.000143	CcSEcCtD
Esomeprazole—Dyspnoea—Doxorubicin—kidney cancer	7.4e-05	0.000142	CcSEcCtD
Esomeprazole—Somnolence—Doxorubicin—kidney cancer	7.38e-05	0.000142	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—GSTT1—kidney cancer	7.32e-05	0.0027	CbGpPWpGaD
Esomeprazole—Dyspepsia—Doxorubicin—kidney cancer	7.3e-05	0.000141	CcSEcCtD
Esomeprazole—Decreased appetite—Doxorubicin—kidney cancer	7.21e-05	0.000139	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.16e-05	0.000138	CcSEcCtD
Esomeprazole—Fatigue—Doxorubicin—kidney cancer	7.15e-05	0.000138	CcSEcCtD
Esomeprazole—Pain—Doxorubicin—kidney cancer	7.1e-05	0.000137	CcSEcCtD
Esomeprazole—Constipation—Doxorubicin—kidney cancer	7.1e-05	0.000137	CcSEcCtD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—kidney cancer	7.07e-05	0.00261	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—PTGS1—kidney cancer	6.86e-05	0.00253	CbGpPWpGaD
Esomeprazole—Feeling abnormal—Doxorubicin—kidney cancer	6.84e-05	0.000132	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Doxorubicin—kidney cancer	6.79e-05	0.000131	CcSEcCtD
Esomeprazole—Urticaria—Doxorubicin—kidney cancer	6.59e-05	0.000127	CcSEcCtD
Esomeprazole—Abdominal pain—Doxorubicin—kidney cancer	6.56e-05	0.000126	CcSEcCtD
Esomeprazole—Body temperature increased—Doxorubicin—kidney cancer	6.56e-05	0.000126	CcSEcCtD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.21e-05	0.00229	CbGpPWpGaD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	6.17e-05	0.00228	CbGpPWpGaD
Esomeprazole—Hypersensitivity—Doxorubicin—kidney cancer	6.11e-05	0.000118	CcSEcCtD
Esomeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	6.09e-05	0.00225	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	6.05e-05	0.00223	CbGpPWpGaD
Esomeprazole—Asthenia—Doxorubicin—kidney cancer	5.95e-05	0.000115	CcSEcCtD
Esomeprazole—Pruritus—Doxorubicin—kidney cancer	5.87e-05	0.000113	CcSEcCtD
Esomeprazole—Diarrhoea—Doxorubicin—kidney cancer	5.68e-05	0.000109	CcSEcCtD
Esomeprazole—Dizziness—Doxorubicin—kidney cancer	5.49e-05	0.000106	CcSEcCtD
Esomeprazole—Vomiting—Doxorubicin—kidney cancer	5.28e-05	0.000102	CcSEcCtD
Esomeprazole—Rash—Doxorubicin—kidney cancer	5.23e-05	0.000101	CcSEcCtD
Esomeprazole—Dermatitis—Doxorubicin—kidney cancer	5.23e-05	0.000101	CcSEcCtD
Esomeprazole—Headache—Doxorubicin—kidney cancer	5.2e-05	0.0001	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—GSTP1—kidney cancer	5.08e-05	0.00187	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTP1—kidney cancer	5.01e-05	0.00185	CbGpPWpGaD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	5.01e-05	0.00185	CbGpPWpGaD
Esomeprazole—Nausea—Doxorubicin—kidney cancer	4.93e-05	9.48e-05	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—GSTM1—kidney cancer	4.66e-05	0.00172	CbGpPWpGaD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	4.6e-05	0.0017	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTM1—kidney cancer	4.6e-05	0.0017	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—CYP1A1—kidney cancer	4.42e-05	0.00163	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTT1—kidney cancer	4.4e-05	0.00163	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—CYP1A1—kidney cancer	4.36e-05	0.00161	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—PTGS1—kidney cancer	4.13e-05	0.00152	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ACY1—kidney cancer	3.89e-05	0.00144	CbGpPWpGaD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	3.73e-05	0.00138	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.32e-05	0.00122	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PDHB—kidney cancer	3.31e-05	0.00122	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—POMC—kidney cancer	3.3e-05	0.00122	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CCBL1—kidney cancer	3.11e-05	0.00115	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTP1—kidney cancer	3.05e-05	0.00113	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	3.01e-05	0.00111	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.81e-05	0.00104	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.8e-05	0.00104	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.77e-05	0.00102	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PPAT—kidney cancer	2.7e-05	0.000995	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GLIPR1—kidney cancer	2.7e-05	0.000995	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.66e-05	0.000983	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.66e-05	0.000981	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.64e-05	0.000973	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.62e-05	0.000968	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—APRT—kidney cancer	2.51e-05	0.000925	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—FH—kidney cancer	2.51e-05	0.000925	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.45e-05	0.000904	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GPC3—kidney cancer	2.36e-05	0.00087	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ACY1—kidney cancer	2.34e-05	0.000863	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CA2—kidney cancer	2.29e-05	0.000846	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ALAD—kidney cancer	2.23e-05	0.000825	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ST3GAL2—kidney cancer	2.18e-05	0.000805	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ALDH1A1—kidney cancer	2.13e-05	0.000787	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SLC5A3—kidney cancer	2.04e-05	0.000754	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PGK1—kidney cancer	2.04e-05	0.000754	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—LDHB—kidney cancer	2e-05	0.00074	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PDHB—kidney cancer	1.99e-05	0.000734	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—POMC—kidney cancer	1.98e-05	0.000732	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CCBL1—kidney cancer	1.87e-05	0.00069	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CA9—kidney cancer	1.74e-05	0.000641	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.7e-05	0.000627	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PPAT—kidney cancer	1.62e-05	0.000598	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.62e-05	0.000598	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—FH—kidney cancer	1.51e-05	0.000556	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—APRT—kidney cancer	1.51e-05	0.000556	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CRABP1—kidney cancer	1.48e-05	0.000545	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GPC3—kidney cancer	1.42e-05	0.000523	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CA2—kidney cancer	1.38e-05	0.000509	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ITPR2—kidney cancer	1.37e-05	0.000507	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ALAD—kidney cancer	1.34e-05	0.000496	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.31e-05	0.000484	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.28e-05	0.000473	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.27e-05	0.000467	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ACHE—kidney cancer	1.25e-05	0.000462	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTT1—kidney cancer	1.25e-05	0.000462	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.23e-05	0.000454	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PGK1—kidney cancer	1.23e-05	0.000454	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—LDHB—kidney cancer	1.2e-05	0.000445	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SCARB1—kidney cancer	1.19e-05	0.000438	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTGS1—kidney cancer	1.17e-05	0.000433	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PSMD7—kidney cancer	1.15e-05	0.000425	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—BCHE—kidney cancer	1.09e-05	0.000403	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SLC5A5—kidney cancer	1.08e-05	0.000398	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CA9—kidney cancer	1.04e-05	0.000386	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SLC2A1—kidney cancer	1.04e-05	0.000384	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.01e-05	0.000373	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CRABP1—kidney cancer	8.88e-06	0.000328	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.81e-06	0.000325	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTP1—kidney cancer	8.68e-06	0.00032	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ITPR2—kidney cancer	8.26e-06	0.000305	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCB1—kidney cancer	8.22e-06	0.000303	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTM1—kidney cancer	7.98e-06	0.000294	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYP1A1—kidney cancer	7.56e-06	0.000279	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTT1—kidney cancer	7.53e-06	0.000278	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ACHE—kidney cancer	7.53e-06	0.000278	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SCARB1—kidney cancer	7.13e-06	0.000263	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTGS1—kidney cancer	7.06e-06	0.00026	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PSMD7—kidney cancer	6.92e-06	0.000255	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—BCHE—kidney cancer	6.56e-06	0.000242	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.48e-06	0.000239	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SLC2A1—kidney cancer	6.26e-06	0.000231	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.21e-06	0.000229	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—POMC—kidney cancer	5.64e-06	0.000208	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTP1—kidney cancer	5.22e-06	0.000193	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCB1—kidney cancer	4.94e-06	0.000182	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTM1—kidney cancer	4.8e-06	0.000177	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.55e-06	0.000168	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTGS2—kidney cancer	4.5e-06	0.000166	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTEN—kidney cancer	3.92e-06	0.000145	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—POMC—kidney cancer	3.39e-06	0.000125	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.77e-06	0.000102	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTGS2—kidney cancer	2.7e-06	9.98e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTEN—kidney cancer	2.36e-06	8.71e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.66e-06	6.14e-05	CbGpPWpGaD
